NasdaqGS:GILDBiotechs
Gilead Sciences (GILD) Valuation Check As Strong Results Yeztugo Uptake And Yescarta Expansion Draw Attention
Gilead Sciences (GILD) is back in focus after a busy stretch, including strong Q4 and 2025 results, rapid take up of HIV prevention drug Yeztugo, and an FDA label expansion for cell therapy Yescarta.
See our latest analysis for Gilead Sciences.
The recent run of earnings, guidance, dividend increase, and the Yescarta label update has coincided with strong momentum, with a 30 day share price return of 24.91% and a 1 year total shareholder return of 53.07% building on a 5 year total shareholder...